Tennessee Becomes 2nd State to Ban PBMs From Owning Pharmacies

Why It Matters

The ban tackles a longstanding conflict of interest, potentially lowering drug costs and reshaping the pharmacy market, while also signaling heightened regulatory pressure on PBMs nationwide.

Key Takeaways

• Tennessee law forces PBMs to divest pharmacy operations by Jan 1 2027
• CVS warns potential closure of 134 Tennessee stores, 2,000 jobs
• Opposition spent over $7 million and 60 lobbyists against the bill
• Arkansas precedent faces 8th Circuit challenge; Tennessee likely similar
• Federal PBM reform bills gain traction alongside state-level bans

Pulse Analysis

Tennessee’s new pharmacy law marks a decisive step in the ongoing debate over PBM ownership. By prohibiting PBMs from running retail pharmacies, the state aims to eliminate the conflict of interest that critics say inflates drug prices through practices like spread pricing. The legislation, championed by the Tennessee Pharmacists Association and the National Community Pharmacists Association, reflects a broader consumer‑protection agenda that seeks greater transparency in the prescription‑drug supply chain.

The immediate fallout centers on CVS Health, which operates both a PBM (Caremark) and a network of 134 pharmacies in the Volunteer State. CVS warned that compliance could force the closure of those locations, threatening about 2,000 jobs—a claim that lawmakers disputed but underscores the economic stakes. The law gives affected firms until Jan. 1 2027 to divest or restructure, a timeline that will likely trigger a wave of asset sales, mergers, or spin‑offs as companies scramble to meet the deadline while preserving market share.

Tennessee follows Arkansas, the first state to enact a similar ban, and both are expected to face legal challenges rooted in the Commerce Clause. Meanwhile, federal policymakers are moving in parallel, with a revived congressional bill targeting PBM‑insurer integration and recent Medicare Part D reforms in the Consolidated Appropriations Act of 2026. Together, these actions suggest a shifting regulatory landscape that could redefine PBM business models, encourage competition among independent pharmacies, and ultimately influence prescription‑drug pricing across the United States.